Showing results 1-10 of 60 for 'genetics'
Prof. Eran Hornstein discovered that a small molecule already on the market for a different disease can also be active in treating ALS. As Globes reports, NeuroSense Therapeutics will develop the technology; since ALS is considered a priority, NeuroSense believes that it will be able to bring the drug to market within five years.
Our livers perform a host of vital functions, including clearing our bodies of toxins and producing most of the carrier proteins in our blood. Weizmann researchers have now shown that the liver’s amazing multitasking capacity is due at least in part to a clever division of labor among its cells. In fact, they say, “We’ve found that liver cells can be divided into at least nine different types, each specializing in its own tasks.”
Our hearts mean many things: love, strength, loyalty. But even if we look at hearts from a purely biological perspective, they are still awesome – and complicated, particularly when it comes to disease. That’s why, for American Heart Month, we’d like to share some of the many approaches Weizmann Institute scientists are taking to fight heart disease.
Two new and powerful research methods – CRISPR gene editing and single-cell genomic profiling – have now been combined to produce a tool fine enough to enable scientists to observe life’s most nuanced processes. Prof. Ido Amit and his lab have so refined CRISPR that scientists can understand biological processes in shades of grey – not just black and white.
Many years ago, Prof. Michael Sela and colleagues found that antibodies inhibiting EGFR, a receptor that plays a role in cancer, have a synergistic anti-cancer effect when used with chemotherapy. That discovery has now led to three cancer-treating drugs: Erbitux®, Vectibix®, and, most recently, Portrazza™, just FDA approved for a form of lung cancer.
Prof. Moshe Oren has spent decades studying the p53 gene, which plays a key role in keeping healthy cells from turning cancerous. His basic research has inspired other scientists to build on his findings, potentially leading to p53-based cancer treatments. As head of the Moross Integrated Cancer Center, Prof. Oren’s knowledge will be more valuable than ever.
The Weizmann Institute of Science’s Moross Integrated Cancer Center (MICC) aims to revolutionize cancer prevention, detection, and treatments. Several of the senior scientists involved with the MICC – Prof. Zvi Livneh, Prof. Moshe Oren, Dr. Tamar Paz-Elizur, Dr. Eran Elinav, and Dr. Ayelet Erez – discuss directions in cancer prevention research.
As we age, our biological clocks wind down – but why? Dr. Gad Asher, who studies circadian clocks – genetic mechanisms that keep us in tune with cycles of day and night – has identified a link between the clocks and a group of metabolites called polyamines. Found in many foods, polyamines could fight aging – as they did in Dr. Asher’s mice.
As we age, our biological clocks wind down – but why? Weizmann’s Dr. Gad Asher has found a link between the clocks and a group of metabolites called polyamines. Found in many foods, polyamines could help us fight aging. MSN.com reports on the research and a polyamine-laden diet, including soybeans, corn, green peas, blue cheese.
After earning his master's at Weizmann's Feinberg Graduate School, Eran Hodis, 29, discovered two of the most common genetic mutations in all of cancer. Now an MD-PhD candidate at Harvard and MIT, he credits Weizmann—and in particular, his mentors Profs. Eran Segal and Joel Sussman—with launching his scientific career.